Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the <scp>BOSTON</scp> trial

A subgroup analysis of efficacy, safety and QOL in patients who received selinexor in combination with bortezomib and dexamethasone (SVd) with and without selinexor dose reduction and who had lenalidomide-refractory disease in the phase 3 BOSTON trial showed improvements in efficacy, quality of life (QOL) and safety outcomes with selinexor dose reduction in this difficult-to-treat population. These findings demonstrate the benefit of selinexor dose reductions in optimizing the treatment of patients with lenalidomide-refractory multiple myeloma (MM) receiving SVd.

Authors

Institutions

Publication Details

Journal
British Journal of Haematology
Published
2026-04-14
DOI
https://doi.org/10.1111/bjh.70479
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial

I Spicka, Ceri Bygrave, S Delimpasi, DON A. STEVENS et al.
British Journal of Haematology
Multiple Myeloma Research and Treatments
article

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial

I Spicka, Ceri Bygrave, S Delimpasi, DON A. STEVENS, Charles la Porte, G Merlo, M A Dimopoulos, Mercedes Gironella Mesa, Jason P. Butler
article en

Abstract

A subgroup analysis of efficacy, safety and QOL in patients who received selinexor in combination with bortezomib and dexamethasone (SVd) with and without selinexor dose reduction and who had lenalidomide-refractory disease in the phase 3 BOSTON trial showed improvements in efficacy, quality of life (QOL) and safety outcomes with selinexor dose reduction in this difficult-to-treat population. These findings demonstrate the benefit of selinexor dose reductions in optimizing the treatment of patients with lenalidomide-refractory multiple myeloma (MM) receiving SVd.

British Journal of Haematology
Korea University (KR), Norton Healthcare (US), Charles University (CZ), Royal Brisbane and Women's Hospital (AU), University Hospital of Wales (GB), Menarini Group (Italy) (IT), Alexandra Hospital (GR), Vall d'Hebron Hospital Universitari (ES), General University Hospital in Prague (CZ), Evangelismos Hospital (GR)
Menarini Group
Openalex Percentile: Top 16%
Multiple Myeloma Research and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the <scp>BOSTON</scp> trial — I Spicka, Ceri Bygrave, et al. · British Journal of Haematology (2026) | TGRS Research Map | TGRS